Avista Pharma Solutions has completed facility upgrades at its site in Longmont, Colorado, US, expanding the manufacturing footprint of its drug products by 20,000ft².

Furthermore, the company will be able to formulate and manufacture new dosage forms.

The expansion includes the addition of four new current good manufacturing practice (cGMP) processing suites and all associated manufacturing support areas.

Avista Pharma’s drug product capabilities will now include encapsulation, high-shear granulation, fluid-bed granulation, drying and coating, tablet compression, and packaging.

In addition, the company’s operations team now supports the formulation and manufacture of dosage forms such as immediate-release tablets and capsules, enteric-release tablets, modified-release, multi-particulate tablets, and capsules.

“By offering optimised formulation and manufacturing of a wider range of dosage forms, we can now help make more life preserving medicines a reality.”

Other dosage forms include hydrophilic and hydrophobic matrix extended-released tablets, opiate tamper-resistant, modified-release pills, and coated aqueous insoluble active ingredients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new manufacturing suites have been designed and monitored to ISO 7 requirements and the expanded support areas meet ISO 8 requirements. This includes a wash and prep area, in addition to clean equipment storage.

Longmont facility general manager Ken Domagalski said: “Expanding our drug product capabilities enables us to better serve our clients as a trusted, effective and innovative partner in all phases of the drug development lifecycle.

“By offering optimised formulation and manufacturing of a wider range of dosage forms, we can now help make more life-preserving medicines a reality.”